GUANGZHOU, China, Aug. 19, 2024 — Burning Rock Biotech Limited (the “Company” or “Burning Rock”) announces that it will submit requests to the London Stock Exchange (the “LSE”), to cancel the admission to trading of its American Depositary Shares representing the class A ordinary shares of the Company (the “ADSs”), and to the UK Financial Conduct Authority, to cancel the listing of the ADSs on the Official List.
The Company has decided to delist its ADSs from the LSE due to low trading volume and liquidity. The delisting is also intended to reduce the costs associated with maintaining the listing. The delisting is expected to take effect on or around September 18, 2024.
Following the Delisting, the ADSs will continue to trade on the Nasdaq Global Market.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: www.brbiotech.com.
Contact:
